KDR and neoplasm: In 2019, Rosenberg and colleagues from National Cancer Institute concluded a clinical trial (NCT01218867) using CAR-T cells targeting anti-vascular endothelial growth factor receptor (VEGFR2) for patients with renal cancer with no objective responses, although promising results were obtained in several different models where VEGFR2 CAR-T cells inhibited tumor growth.